Ocuphire Pharma (OCUP)
(Delayed Data from NSDQ)
$1.58 USD
+0.03 (1.94%)
Updated Jul 3, 2024 01:00 PM ET
After-Market: $1.59 +0.01 (0.63%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth D Momentum F VGM
Income Statements
Fiscal Year end for Ocuphire Pharma, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 19 | 40 | 1 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 19 | 40 | 1 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 30 | 22 | 23 | 20 | 11 |
Income After Depreciation & Amortization | -11 | 18 | -23 | -20 | -11 |
Non-Operating Income | 1 | 0 | -34 | 2 | 3 |
Interest Expense | 0 | 0 | 0 | 7 | 0 |
Pretax Income | -10 | 18 | -57 | -25 | -9 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -10 | 18 | -57 | -25 | -9 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -10 | 18 | -57 | -25 | -9 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -11 | 18 | -23 | -20 | -11 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -11 | 18 | -23 | -20 | -11 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 21.59 | 20.60 | 14.85 | 4.66 | NA |
Diluted EPS Before Non-Recurring Items | -0.46 | 0.87 | -0.72 | -5.28 | NA |
Diluted Net EPS (GAAP) | -0.46 | 0.87 | -3.82 | -5.28 | -8.72 |
Fiscal Year end for Ocuphire Pharma, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 1.71 | 1.69 | 11.94 | 3.67 | 1.75 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 1.71 | 1.69 | 11.94 | 3.67 | 1.75 |
SG&A, R&D, and Dept/Amort Expenses | 9.42 | 7.12 | 5.55 | 9.06 | 7.89 |
Income After SG&A, R&D, and Dept/Amort Expenses | -7.71 | -5.43 | 6.39 | -5.39 | -6.14 |
Non-Operating Income | 0.60 | 0.63 | -0.81 | 0.43 | 0.34 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -7.11 | -4.80 | 5.58 | -4.96 | -5.79 |
Income Taxes | -7.11 | 0.00 | 0.01 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -7.11 | -4.80 | 5.56 | -4.96 | -5.79 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -7.11 | -4.80 | 5.56 | -4.96 | -5.79 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 24.52 | 22.99 | 22.41 | 20.96 | 20.94 |
Diluted EPS Before Non-Recurring Items | -0.29 | -0.21 | 0.25 | -0.24 | -0.28 |
Diluted Net EPS (GAAP) | -0.29 | -0.19 | 0.25 | -0.24 | -0.28 |